Ghost Tree Capital, LLC Reata Pharmaceuticals Inc Transaction History

Ghost Tree Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$79.22 - $105.37 $1.19 Million - $1.58 Million	15,000 Added 21.43%	85,000 $8.67 Million
Q1 2023 May 15, 2023	SELL	$30.85 - $93.17 $13.3 Million - $40.1 Million	-430,000 Reduced 86.0%	70,000 $6.36 Million
Q4 2022 Feb 14, 2023	SELL	$22.15 - $42.11 $4.98 Million - $9.47 Million	-225,000 Reduced 31.03%	500,000 $19 Million
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $14.1 Million - $26.5 Million	725,000 New	725,000 $18.2 Million
Q1 2022 May 16, 2022	SELL	$24.12 - $39.6 $1.33 Million - $2.18 Million	-55,000 Closed	0 $0
Q4 2021 Feb 16, 2022	BUY	$25.61 - $110.96 $1.41 Million - $6.1 Million	55,000 New	55,000 $1.45 Million
Q4 2020 Feb 16, 2021	SELL	$102.03 - $184.62 $3.06 Million - $5.54 Million	-30,000 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$93.53 - $163.34 $1.87 Million - $3.27 Million	-20,000 Reduced 40.0%	30,000 $2.92 Million
Q1 2020 May 15, 2020	SELL	$124.16 - $247.74 $3.1 Million - $6.19 Million	-25,000 Reduced 33.33%	50,000 $7.22 Million
Q4 2019 Feb 14, 2020	BUY	$74.57 - $217.92 $1.86 Million - $5.45 Million	25,000 Added 50.0%	75,000 $15.3 Million
Q3 2019 Nov 14, 2019	BUY	$71.26 - $95.75 $3.56 Million - $4.79 Million	50,000 New	50,000 $4.02 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Ghost Tree Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ghost Tree Capital, LLC with notifications on news.